Medicare expands home infusion coverage for chronic patients
H.R. 4993 — Joe Fiandra Access to Home Infusion Act of 2025 · Filed by Brian Fitzpatrick (R-PA) · 6 cosponsors · Introduced Aug 19, 2025 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands Medicare coverage to include external infusion pumps and certain home-administered drugs that require professional supervision, starting one year after enactment. Patients with conditions requiring frequent IV or subcutaneous infusions (at least 12 times per year) can now receive these treatments at home under a qualified supplier's supervision, and Medicare must notify patients of their cost-sharing obligations compared to other care settings.
Why we flagged it
The bill's operative mechanism is a straightforward expansion of Medicare's covered services — it removes a regulatory barrier to home infusion therapy for a defined population (patients requiring frequent professional-supervised infusions) and mandates cost-sharing disclosure. This is a coverage policy change, not a tax provision, subsidy, or deregulation.
What the text implies
- The one-year implementation delay may create a gap during which beneficiaries cannot access home infusion under this new pathway, potentially affecting treatment decisions and care planning.
- The bill does not specify reimbursement rates for qualified home infusion therapy suppliers, leaving rate-setting to CMS — suppliers' financial viability depends on regulatory follow-through.
- Cost-sharing notification requirement may reveal significant out-of-pocket differences between home and facility-based infusion, potentially steering lower-income beneficiaries toward facility care despite home preference.
- The definition of 'qualified home infusion therapy supplier' is cross-referenced to existing regulations (subsection (iii)(3)(D)) not quoted in this bill; the actual qualification standards are not visible in this text.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Medicare beneficiaries with chronic conditions requiring frequent infusions gain access to home-based care, reducing hospitalizations and improving quality of life. The bill includes a safeguard requiring qualified supplier administration and FDA-approved professional supervision, and mandates cost-sharing transparency so patients can make informed choices about care settings.
Who stands to gain
- home infusion therapy suppliers
- durable medical equipment (DME) companies manufacturing external infusion pumps
- specialty pharmaceutical distributors
Named in the bill
Medicare, Social Security Act, Food and Drug Administration (FDA), Department of Health and Human Services (HHS), qualified home infusion therapy supplier, external infusion pump manufacturers, specialty pharmaceutical companies
Where it stands
6 cosponsors: 4 Democrats, 2 Republicans.
- Aug 19, 2025 — Introduced · Congress.gov: “Introduced in House”
- Aug 19, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”
- Dec 10, 2025 — Markup held in committee · Congress.gov: “Committee Consideration and Mark-up Session Held”
- Dec 10, 2025 — Reported out of committee · Congress.gov: “Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 41 - 0”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
3 lobbying clients named this bill on 4 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,250,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 61% of bills with at least one filing.
Brian Fitzpatrick, the sponsor, reported $2,362,211 in PAC receipts in the 2026 cycle.
- Alnylam Pharmaceuticals, Inc. — $840,000 on 2 filings
- Ucb, Inc. — $350,000 on 1 filing
- Chiesi Usa, Inc. — $60,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (1,922 characters) on Aug 20, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Medicare expands home infusion coverage for chronic patients” QuorumCivic. https://share.quorumcivic.app/bill/119/hr4993 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.